CompletedPhase 4

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

United States20 participantsStarted 2020-12-01

Plain-language summary

This study aims to determine if capsaicin cream offers symptomatic relief to patients suffering from Cannabinoid Hyperemesis Syndrome (condition that leads to repeated and severe bouts of vomiting).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years old * Diagnosis of cannabinoid hyperemesis syndrome Exclusion Criteria: * Patients who receive more than 2 anti-emetic therapies prior to screening for enrollment * Patients who receive haloperidol as an anti-emetic therapy * Pregnant women * Prisoners

What they're measuring

Time to resolution of symptoms

Timeframe: 1 day (During emergency department admission)

Trial details

NCT IDNCT04283292

SponsorUniversity of Virginia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-18

View on ClinicalTrials.gov More Cannabinoid Hyperemesis Syndrome trials